Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED VACCINE CANDIDATES FOR SARS-CoV-2 NEW VARIANTS IN HEALTHY INDIVIDUALS

NCT05997290 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT05997290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05997290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED VACCINE CANDIDATES FOR SARS-CoV-2 NEW VARIANTS IN HEALTHY INDIVIDUALS
Lead sponsor
BioNTech SE
Phase
Phase 2/3
Overall status
Completed
Start date
August 10, 2023
Completion date
March 13, 2025
Enrollment
1,051 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection